AU566234B2 - Pyridine-soluble extract and refined detoxified endotoxin composition - Google Patents

Pyridine-soluble extract and refined detoxified endotoxin composition

Info

Publication number
AU566234B2
AU566234B2 AU33400/84A AU3340084A AU566234B2 AU 566234 B2 AU566234 B2 AU 566234B2 AU 33400/84 A AU33400/84 A AU 33400/84A AU 3340084 A AU3340084 A AU 3340084A AU 566234 B2 AU566234 B2 AU 566234B2
Authority
AU
Australia
Prior art keywords
pyridine
soluble extract
detoxified endotoxin
endotoxin composition
refined detoxified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33400/84A
Other languages
English (en)
Other versions
AU3340084A (en
Inventor
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of AU3340084A publication Critical patent/AU3340084A/en
Application granted granted Critical
Publication of AU566234B2 publication Critical patent/AU566234B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU33400/84A 1983-09-23 1984-09-21 Pyridine-soluble extract and refined detoxified endotoxin composition Ceased AU566234B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use
US535037 1983-09-23

Publications (2)

Publication Number Publication Date
AU3340084A AU3340084A (en) 1985-03-28
AU566234B2 true AU566234B2 (en) 1987-10-15

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33400/84A Ceased AU566234B2 (en) 1983-09-23 1984-09-21 Pyridine-soluble extract and refined detoxified endotoxin composition

Country Status (23)

Country Link
US (1) US4663306A (cg-RX-API-DMAC7.html)
JP (1) JPS60120817A (cg-RX-API-DMAC7.html)
KR (1) KR870000843B1 (cg-RX-API-DMAC7.html)
AT (1) AT385659B (cg-RX-API-DMAC7.html)
AU (1) AU566234B2 (cg-RX-API-DMAC7.html)
BE (1) BE900650A (cg-RX-API-DMAC7.html)
CA (1) CA1244765A (cg-RX-API-DMAC7.html)
CH (1) CH664897A5 (cg-RX-API-DMAC7.html)
DE (1) DE3434766C2 (cg-RX-API-DMAC7.html)
DK (1) DK446684A (cg-RX-API-DMAC7.html)
ES (1) ES8608872A1 (cg-RX-API-DMAC7.html)
FI (1) FI843716L (cg-RX-API-DMAC7.html)
FR (1) FR2552326B1 (cg-RX-API-DMAC7.html)
GB (1) GB2149301B (cg-RX-API-DMAC7.html)
HU (1) HU192585B (cg-RX-API-DMAC7.html)
IL (1) IL73034A (cg-RX-API-DMAC7.html)
IN (1) IN157240B (cg-RX-API-DMAC7.html)
IT (1) IT1179444B (cg-RX-API-DMAC7.html)
NL (1) NL8402902A (cg-RX-API-DMAC7.html)
NO (1) NO843776L (cg-RX-API-DMAC7.html)
NZ (1) NZ209635A (cg-RX-API-DMAC7.html)
SE (1) SE8404707L (cg-RX-API-DMAC7.html)
ZA (1) ZA847405B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
ATE210989T1 (de) * 1993-08-27 2002-01-15 Vetrepharm Inc Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
KR100628007B1 (ko) 1998-07-16 2006-09-26 이치로 아즈마 세균의 균체성분을 유효성분으로 하는 암면역요법용 제제
JP4772245B2 (ja) * 1999-12-13 2011-09-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド 治療上有用な合成オリゴヌクレオチド
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
JP5106736B2 (ja) * 2000-07-11 2012-12-26 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
KR100820521B1 (ko) * 2002-03-05 2008-04-07 셀 메디신 가부시키가이샤 고체화 조직 면역아쥬반트
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
AU2003261624A1 (en) * 2003-09-05 2005-03-29 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
HUE071447T2 (hu) 2014-06-17 2025-08-28 Crown Laboratories Inc Genetikailag módosított baktériumok és eljárások baktériumok genetikai módosítására
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
JP2023533202A (ja) 2020-06-23 2023-08-02 クラウン ラボラトリーズ，インコーポレイテッド プロバイオティクス皮膚製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (cg-RX-API-DMAC7.html) * 1972-06-20 1973-12-27
FR2269962B1 (cg-RX-API-DMAC7.html) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
SE8404707L (sv) 1985-03-24
SE8404707D0 (sv) 1984-09-20
IT1179444B (it) 1987-09-16
NZ209635A (en) 1989-01-27
BE900650A (fr) 1985-03-21
FI843716A7 (fi) 1985-03-24
ATA302384A (de) 1987-10-15
JPS6254775B2 (cg-RX-API-DMAC7.html) 1987-11-17
ZA847405B (en) 1985-05-29
FI843716A0 (fi) 1984-09-21
GB2149301B (en) 1988-06-22
ES536167A0 (es) 1986-07-16
HUT35521A (en) 1985-07-29
JPS60120817A (ja) 1985-06-28
KR870000843B1 (ko) 1987-04-25
NO843776L (no) 1985-03-25
IT8448894A0 (it) 1984-09-24
DE3434766A1 (de) 1986-04-30
IL73034A (en) 1988-11-15
GB2149301A (en) 1985-06-12
DE3434766C2 (de) 1987-05-14
CH664897A5 (de) 1988-04-15
FI843716L (fi) 1985-03-24
US4663306A (en) 1987-05-05
CA1244765A (en) 1988-11-15
AT385659B (de) 1988-05-10
IN157240B (cg-RX-API-DMAC7.html) 1986-02-15
FR2552326A1 (fr) 1985-03-29
KR850002404A (ko) 1985-05-13
AU3340084A (en) 1985-03-28
HU192585B (en) 1987-06-29
NL8402902A (nl) 1985-04-16
FR2552326B1 (fr) 1988-05-13
ES8608872A1 (es) 1986-07-16
DK446684A (da) 1985-03-24
DK446684D0 (da) 1984-09-19
GB8423993D0 (en) 1984-10-31

Similar Documents

Publication Publication Date Title
AU566234B2 (en) Pyridine-soluble extract and refined detoxified endotoxin composition
AU552403B2 (en) Anthelmintic composition and use
AU570659B2 (en) 1-azolyl-2-aryl-3-fluoroalkan-2-ols and ethers thereof
AU564963B2 (en) N-alkoxyaminosulfonyl-ureas and n-alkyl- sulfonylaminosulfonylureas
AU569930B2 (en) Buprenorphine and naloxone composition
AU577649B2 (en) Siloxane composition
AU5068285A (en) Bischloroformate compositions and their preparation
AU547389B2 (en) Compositions of dextromethorphan and method
AU564694B2 (en) Blends of polyetherimide and organosiloxane-polycarbonate block copolymers
AU7804287A (en) Bookcover and binding method
AU574789B2 (en) Process and composition for permanent waving
GB2161381B (en) Detoxified endotoxin compositions
AU560418B2 (en) Mothproofing and beetleproofing composition
AU2636384A (en) Phenylaminobenzenealkanols and preparation
AU528710B2 (en) Hexahydro-trans and tetrahydropyridoindole
AU6697086A (en) Immunoamplifiers and related compositions
AU4024289A (en) Selenium-sulfur compositions and uses therefor
AU4617185A (en) Ketofin and anti-asthmatically effective xanthine
AU568750B2 (en) Imidazo-pyrrolo-pyridines and their use as herbacides
AU1898983A (en) Perfluoroalkylmaleinamides and perfluoroalkylfumaramides
AU573272B2 (en) Dihydroisoquinolines and tetrahydroisoquinolones
IL72675A0 (en) Refined detoxified endotoxin
AU573031B2 (en) Organopolysiloxane composition
AU568385B2 (en) Pyrrolizinones and indolizinones
AU1763883A (en) Acylpyrazines and use thereof in smoking compositions